The Competition Council of Bosnia and Herzegovina, at its 33rd session held on 28 August 2025 in Sarajevo, considered materials in the field of competition law and policy, as well as the internal work and functioning of the Council.

At the session, a Decision was adopted establishing that the “Health Insurance Fund of the Republic of Srpska” and the “University Clinical Center of the Republic of Srpska”, through the adoption and implementation of the Program of Non-Invasive Prenatal Testing from the Blood of Pregnant Women for 2023, 2024 and 2025, concluded a prohibited agreement within the meaning of Article 4, paragraph (1), items c) and d) of the Competition Law. In this way, competition in the market of non-invasive prenatal testing from the blood of pregnant women (NIPT) in the territory of the entity of the Republic of Srpska was limited and distorted.
The part of the Claim relating to the determination of prohibited competitive practices under Article 4, paragraph (1), item a) and Article 10, paragraph (2), item a) of the Law on Competition was rejected as unfounded.

In addition, the Competition Council issued a Decision allowing the concentration upon Notification of the concentration, which arises from the acquisition of joint control over the target companies Balked Saglik Hizmetleri Anonim Sirketi” and “Bahceci Kadin Sagligi Tip Merkezleri Anonim Sirketi” by the undertaking “CVC Capital Partners plc” “Hartenberg Holding, s.r.o.” and “Porodice Bahceci” on the market for providing assisted reproductive services in Bosnia and Herzegovina.

In accordance with the provision of Article 25 of the Law on Competition, the Draft Law on Dual Education of the Sarajevo Canton was also reviewed. It was determined that the proposed text of the Draft Law does not contain provisions that could prevent, restrict or distort competition in the relevant market in the Sarajevo Canton, within the meaning of the provisions of the Law on Competition, i.e. it is in compliance with the Law on Competition.